BR100 Increased By (0.44%)
BR30 Increased By (1.39%)
KSE100 Increased By (0.62%)
KSE30 Increased By (0.61%)
BECO 5.43 Decreased By ▼ -0.06 (-1.09%)
BML 55.69 Decreased By ▼ -1.07 (-1.89%)
BOP 35.38 Increased By ▲ 0.26 (0.74%)
CNERGY 8.20 Increased By ▲ 0.05 (0.61%)
DCL 11.55 Increased By ▲ 0.04 (0.35%)
FCCL 58.36 Increased By ▲ 1.61 (2.84%)
FCSC 5.12 Decreased By ▼ -0.03 (-0.58%)
FFL 17.84 Decreased By ▼ -0.04 (-0.22%)
FNEL 1.25 No Change ▼ 0.00 (0%)
HUMNL 11.07 Decreased By ▼ -0.05 (-0.45%)
KEL 8.75 Increased By ▲ 0.33 (3.92%)
KOSM 6.69 Increased By ▲ 0.11 (1.67%)
MLCF 107.15 Increased By ▲ 3.85 (3.73%)
NBP 201.73 Increased By ▲ 1.55 (0.77%)
PACE 11.30 Increased By ▲ 0.01 (0.09%)
PAEL 44.49 Increased By ▲ 1.02 (2.35%)
PIAHCLA 29.41 Increased By ▲ 1.92 (6.98%)
PIBTL 18.64 Increased By ▲ 0.94 (5.31%)
PPL 247.98 Increased By ▲ 3.66 (1.5%)
PRL 35.29 Decreased By ▼ -0.14 (-0.4%)
PTC 66.14 Increased By ▲ 0.79 (1.21%)
SEARL 95.49 Increased By ▲ 2.17 (2.33%)
SSGC 32.04 Decreased By ▼ -0.90 (-2.73%)
TELE 8.87 Decreased By ▼ -0.04 (-0.45%)
THCCL 66.61 Decreased By ▼ -0.11 (-0.16%)
TPLP 10.57 Decreased By ▼ -0.26 (-2.4%)
TREET 25.30 Increased By ▲ 0.18 (0.72%)
TRG 64.40 Decreased By ▼ -0.50 (-0.77%)
WAVES 10.90 Decreased By ▼ -0.03 (-0.27%)
WTL 1.26 Increased By ▲ 0.01 (0.8%)
World

Philippines to evaluate China's Sinopharm COVID-19 vaccine for emergency use

  • Sinopharm is the sixth vaccine maker to apply for emergency use authorisation in the Southeast Asian country.
Published March 2, 2021 Updated March 2, 2021 01:36pm
By

MANILA: China's Sinopharm has applied for emergency use of its COVID-19 vaccine in the Philippines, the chief of Manila's Food and Drug Administration (FDA) said on Tuesday.

Sinopharm is the sixth vaccine maker to apply for emergency use authorisation in the Southeast Asian country.

The Philippines, which has the second-highest number of COVID-19 cases and deaths in Southeast Asia, has approved the vaccines of Pfizer, AstraZeneca and Sinovac for emergency use.

Comments

Comments are closed for this article.